Long-Sheng Chang
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Area:
Molecular BiologyGoogle:
"Long-Sheng Chang"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chang LS, Oblinger JL, Smith AE, et al. (2021) Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. Plos One. 16: e0252048 |
| Chang LS, Oblinger JL, Burns SS, et al. (2019) Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas. Molecular Cancer Therapeutics |
| Allaway R, Angus SP, et al. (2018) Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350 |
| Beauchamp R, Erdin S, Angus S, et al. (2018) CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA Neuro-Oncology. 20: vi52-vi52 |
| Fuse MA, Klingeman Plati S, Burns SS, et al. (2017) Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics |
| Oblinger JL, Burns SS, Huang J, et al. (2017) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology |
| Petrilli AM, Garcia J, Bott M, et al. (2017) Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget |
| Burns SS, Chang LS. (2016) Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma. Methods in Molecular Biology (Clifton, N.J.). 1427: 59-72 |
| Oblinger JL, Burns SS, Akhmametyeva EM, et al. (2016) Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology |
| Chow HY, Dong B, Duron SG, et al. (2015) Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 6: 1981-94 |